NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.94) by $0.03. The biopharmaceutical company earned $18.74 million during the quarter, compared to analyst estimates of $23.33 million. MacroGenics had a negative net margin of 303.08% and a negative return on equity of 59.67%. View MacroGenics' Earnings History.

MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for MacroGenics.

11 brokers have issued 12-month price targets for MacroGenics' stock. Their forecasts range from $6.00 to $50.00. On average, they expect MacroGenics' share price to reach $24.48 in the next year. This suggests a possible upside of 149.0% from the stock's current price. View Analyst Price Targets for MacroGenics.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.

Media stories about MGNX stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MacroGenics earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for MacroGenics.

MacroGenics saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3,630,000 shares, a decrease of 16.9% from the September 30th total of 4,370,000 shares. Based on an average trading volume of 467,700 shares, the short-interest ratio is currently 7.8 days. Approximately 8.3% of the shares of the company are sold short. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), Dicerna Pharmaceuticals (DRNA), ChemoCentryx (CCXI), Madrigal Pharmaceuticals (MDGL), Gossamer Bio (GOSS), Epizyme (EPZM), Akcea Therapeutics (AKCA), Zymeworks (ZYME), Karuna Therapeutics (KRTX), Alder Biopharmaceuticals (ALDR), Axsome Therapeutics (AXSM), Apellis Pharmaceuticals (APLS), Corcept Therapeutics (CORT) and Myovant Sciences (MYOV).

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), NVIDIA (NVDA), Celgene (CELG), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), Incyte (INCY), Karyopharm Therapeutics (KPTI), Micron Technology (MU) and TherapeuticsMD (TXMD).

MacroGenics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (3.86%), Rhenman & Partners Asset Management AB (1.64%), Point72 Asset Management L.P. (0.75%), Granahan Investment Management Inc. MA (0.46%), Squarepoint Ops LLC (0.32%) and Massachusetts Financial Services Co. MA (0.29%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Jon Marc Wigginton, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.

MGNX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Man Group plc, Point72 Asset Management L.P., Rhenman & Partners Asset Management AB, Alps Advisors Inc. and Barclays PLC. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View Insider Buying and Selling for MacroGenics.

MGNX stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Massachusetts Financial Services Co. MA, Squarepoint Ops LLC, Campbell & CO Investment Adviser LLC, Granahan Investment Management Inc. MA, Tower Research Capital LLC TRC, Rhumbline Advisers and Metropolitan Life Insurance Co NY. View Insider Buying and Selling for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $9.83.

MacroGenics has a market capitalization of $480.85 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.

The official website for MacroGenics is http://www.macrogenics.com/.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.